Faheema Hasan/LinkedIn
Sep 2, 2026, 14:07
Faheema Hasan: A New Second-Line Therapy for Essential Thrombocythemia
Faheema Hasan, Associate Professor at United Medicity, shared a post on LinkedIn:
“FDA Approves Besremi (ropeginterferon alfa) for Essential Thrombocythemia as second line after hydroxyurea, the first new drug in ET after nearly 3 decades.
Not only does it provides improvement in platelet counts but it also decreases JAK2 mutational burden proving its disease modifying effect as well…
Key points from the approval:
- Dosing: Starts at 250 mcg SC, stepped up to 350 mcg at 2 weeks, then a maintenance dose of 500 mcg every 2 weeks (adjusted for tolerability)
- Evidence base: The SURPASS ET trial compared Besremi to anagrelide in 174 adults with ET who had an inadequate response to or intolerance of hydroxyurea
- Efficacy: Durable modified ELN response (blood count remission plus stable/improved spleen size plus no bleeding/clotting events) was seen in 37.4 percent of Besremi-treated patients versus 3.6 percent on anagrelide at both 9 and 12 months
- Safety: Most common adverse effects were transaminase elevation, anemia, fever, bacterial infection, pruritus, and weight loss
This gives us another evidence-backed second-line option for ET patients who don’t respond well to or can’t tolerate hydroxyurea — an interferon-based therapy with a meaningfully higher durable response rate than anagrelide in this setting.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge